Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132243) titled 'A Prospective Clinical Trial of Preliminary Efficacy and Safety of the Combination of 177Lu-FAP-2286 and 177Lu-DOTATATE (Cocktail Therapy) for Advanced Grade 3 Gastroenteropancreatic Neuroendocrine Tumors (FAP-TATE Trial)' on Sept. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The affiliated hospital of southwest medical university
Condition:
Grade G3 Gastroenteropancreatic Neuroendocrine Tumor
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-15
Target Sample Size: Experimental group:20;
Countries of Recruitment:
China
To know more, v...